New technique developed to control cervical cancer

January 28, 2014

Gene related to the proliferation of cancerous cells blocked through molecular technology.

A group of researchers from Mexico's General Hospital, Health Secretariat, Medicine Faculty and the Institute of Cellular Physiology of the National Autonomous University of Mexico (UNAM) identified a therapeutic target for cervix cancer: gene CDKN3.

The researched performed at the lab indicates that when this gene is blocked in culture , the neoplastic proliferation greatly diminishes.

Jaime Berumen Campos, who coordinates the research said that this gene is blocked by a "siRNA" (small interference RNA), molecular technique applied to several strands of cervix cancer cells making them incapable of proliferating, and confirmed that tumors in mice stopped growing.

To achieve this, researchers first analyzed eight thousand and 638 genes in 43 samples of cervix cancer cells, identifies six suspect of making grow.

One of these is CDKN3, which apparently is the most important, given that its activity was highly elevated in most of explored cancers.

Later, clinical evolution of 42 patients was studied during five years, and was found that when CDKN3 is very active, patients have little survival, Berumen Campos explained, who because of this research won the Award of Medical Research "Dr. Jorge Rosenkranz" 2013, in the clinical area.

"70 per cent of the patients with a high activity of this gene, died less than two years of developing the illness, meanwhile only 15 per cent of patients with a low activity of this indicator died while the study was being performed".

Experimentation in culture cells and observation in women with cancer, indicate that this gene is linked to the aggressiveness and malignant growth of the tumor. Besides, the findings indicate that this gene could be a good , meaning, that overriding its primary function (promoting cellular growth), it would be possible to diminish the proliferation of tumors in women.

Cervical cancer is treated by surgery, chemo and radiotherapy or a combination of all the above, according to the clinical stage. The success and survival diminish as the disease advances.

The percentage of women who survive five years is reduced by 93 percent in the first stage, and to 15 percent in the fourth stage. Contrary to other types of cancer, for which drugs against specific molecular targets exist, this have not been developed for cervical cancer.

Finally, Berumen Campos said that this found methodology still requires clinical trial and validation, but preliminary results look promising and will become an important tools for oncologist to identify women with cervical cancer that have a high risk of dying in less than two years and, therefore, require a more intense medical treatment.

Explore further: Cervical cancer and pre-cancer cervical growths require single HPV protein

Related Stories

Study finds genomic differences in types of cervical cancer

August 23, 2013

A new study has revealed marked differences in the genomic terrain of the two most common types of cervical cancer, suggesting that patients might benefit from therapies geared to each type's molecular idiosyncrasies.

Screening helps prevent cervical cancer in older women

January 14, 2014

New research from Queen Mary University of London reveals women over the age of 50 who don't attend cervical screening are four times more likely to be diagnosed with cervical cancer in later life.

Recommended for you

Researchers thwart cancer cells by triggering 'virus alert'

August 27, 2015

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.